跳至主要内容
临床试验/JPRN-UMIN000018749
JPRN-UMIN000018749已完成未知

The effects of galantamine administration on brain network topology in patients with Alzheimer's disease (AD): A possible new biomarker for pharmacotherapy of AD - The effects of galantamine administration on brain network topology in patients with Alzheimer's disease

atinal Center of Neurology and Psychiatry0 个研究点目标入组 9 人开始时间: 2015年8月21日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
9

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) Co-existing other neurodegenerative disease. 2) A history indicating excessive nicotine or alcohol intake (>0.5 packs of cigarettes, >4 glasses of an alcoholic substance a day), a severe allergy to pharmacological substances or their constitutive compounds, or the use of any experimental medication within 3months prior to the enrolment in the trial. 3) Patients with cardiovascular disease (e.g. myocardial infarction, valvulitis, or cardiomyopathy) or electrolyte imbalance (e.g. hypokalaemia). 4) Patients with severe liver dysfunction (Child-Pugh score of C) or severe renal dysfunction. 5) Exclusion criteria to MRI: presence of a pacemaker, metallic implants in high-risk areas (i.e. aneurysm clips) and a history of claustrophobia.

研究者

发起方
atinal Center of Neurology and Psychiatry

相似试验